Cetilistat
Trade name: oblean
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2004 (NCT00156897)
Timeline
Indications
Mechanism of action
- Lipoprotein lipaseINHIBITOR
LPL inhibitor
- Pancreatic lipaseINHIBITOR
Pancreatic lipase inhibitor
- Gastric lipaseINHIBITOR
Gastric lipase inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CCCCCCCCCCCCCCCCOc1nc2ccc(C)cc2c(=O)o1- Mol. weight
- 401.59 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2103825 ↗
Also known as
- 2-(hexadecyloxy)-6-methyl-4h-3,1-benzoxazin-4-one
- atl-962
- atl-962
- atl-962
- atl-962
- cetilistat
- cetilistat
- cetilistat
- cetilistat
- cetilistat
- cetilistat
- oblean
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00148382 | Phase 1 | Apr 1, 2005 | Alizyme, PharmaNet (2006) |
| NCT00156897 | Phase 2 | Dec 1, 2004 | Alizyme, Barts & The London NHS Trust |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Alizyme | For profit | 2 | 2 | 2 | 2004 |
| Barts & The London NHS Trust | Academic/Hospital | 1 | 0 | 1 | 2004 |
| PharmaNet (2006) | For profit | 1 | 0 | 1 | 2005 |
3 organizations
Page 1 / 1